Europe Transdermal Drug Delivery System Market Forecast to 2030 - Regional Analysis - by Type, Application, and Distribution Channel

The Europe transdermal drug delivery system market is expected to grow from US$ 10.43 billion in 2022 to US$ 14.42 billion by 2030. It is estimated to register a CAGR of 4.1% from 2022 to 2030.

Growing Demand for Noninvasive Drug Delivery Devices Fuels Europe Transdermal Drug Delivery System Market

Traditional drug delivery techniques such as intramuscular, intravenous, and rectal drug administration are not preferred by certain patient populations mainly due to the pain and complexities associated with them. With the improvements in medical science and definite drug delivery technologies, noninvasive drug delivery systems are now set to compete with the traditional method of injectable route of drug administration. The noninvasive drug delivery systems include drug delivery via oral; topical; transdermal-active (device-aided enhanced penetration) and transdermal-passive; and transocular membrane, transmucosal membrane, and alveolar membrane from inhaled medication. Transdermal drug delivery is advantageous in many ways over the oral route of administration. In particular, it evades the first-pass mechanism of the liver, which can otherwise impulsively metabolize drugs.

Further, transdermal delivery is not as painful as hypodermic injections, and this route leads to no dangerous medical waste and poses no risk of disease transmission by needle reuse, which is especially common in developing and under-developed countries. In addition, a noninvasive transdermal drug delivery system has simplified dosing schedules, and the drugs can be self-administered. Patient compliance is much higher when drugs are administrated noninvasively due to low or no pain involved. Therefore, this route is considered a preferred mode of drug delivery. Moreover, a non-invasive drug delivery system can significantly reduce the cost of clinical use because of the self-administration of the drugs by the patients. Thus, the advantages associated with a noninvasive drug delivery facilitated by transdermal drug delivery systems drive the market growth.

Europe Transdermal Drug Delivery System Market Overview

The Europe transdermal drug delivery system market is segmented into the UK, France, Germany, Spain, Italy, and the Rest of Europe. In 2022, the Germany held the largest share of the Europe transdermal drug delivery system market. The market is expected to grow significantly owing to the growing need for pain management and the increasing prevalence of cardiovascular diseases in the region. Cardiovascular diseases such as heart failure, myocardial infarction, coronary cardiac disease, and inflammatory heart disease account for the broadest health problems in the region. Germany is known for its advancement in technology that helps lead the country to the forefront in the medical and healthcare sectors. According to a study published in 2021 in the National Center for Biotechnology Information (NCBI), cardiovascular disease prevalence is often higher in East Germany. The country has also witnessed increasing innovations through market players in recent years. In May 2023, BioNxt Solutions Inc. received government approval to proceed with a comparative drug absorption study for a transdermal Rotigotine patch designed to treat Parkinson's disease. The company has R&D operations in North America and Europe, with an operational focus in Germany, and is currently undergoing regulatory approval and commercialization of medical products for European markets.

In March 2019, LTS Lohmann Therapie-Systeme AG and LEO Pharma A/S together started a clinical trial of microarray patches for the local intradermal treatment of psoriasis.

Germany is also among the primary countries that export healthcare products and services. In addition, the asset of technological advancement has set international standards for quality, safety, and reliability. Moreover, the German manufacturers and service providers in all health and medical segments fascinate foreign customers and partners by delivering healthcare innovation. Such developments in transdermal patches fuel the growth of the transdermal drug delivery system market in Germany.

Europe Transdermal Drug Delivery System Market Segmentation

The Europe transdermal drug delivery system market is segmented into type, application, distribution channel, and country.

Based on type, the Europe transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held the largest share of the Europe transdermal drug delivery system market in 2022. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.

In terms of application, the Europe transdermal drug delivery system market is categorized into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held the largest share of the Europe transdermal drug delivery system market in 2022. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.

By distribution channel, the Europe transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the Europe transdermal drug delivery system market in 2022.

Based on country, the Europe transdermal drug delivery system market is categorized into the UK, France, Germany, Spain, Italy, and the Rest of Europe. Germany dominated the Europe transdermal drug delivery system market in 2022.

Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, UCB SA, and Viatris Inc are some of the leading companies operating in the Europe transdermal drug delivery system market.